Table II.
Comparing NxTAG‐RPP and RF‐22 for Individual Targets
| A. Overall | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pathogen | TP | FP | FN | TN | Total | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Κ |
| PIV‐1 | 3 | 0 | 0 | 279 | 282 | 100 | 100 | 100 | 100 | 1.00 |
| PIV‐2 | 4 | 0 | 0 | 278 | 282 | 100 | 100 | 100 | 100 | 1.00 |
| PIV‐4 | 3 | 0 | 0 | 279 | 282 | 100 | 100 | 100 | 100 | 1.00 |
| HMPV | 15 | 0 | 0 | 267 | 282 | 100 | 100 | 100 | 100 | 1.00 |
| RSV A | 13 | 0 | 0 | 269 | 282 | 100 | 100 | 100 | 100 | 1.00 |
| RSV B | 13 | 0 | 0 | 269 | 282 | 100 | 100 | 100 | 100 | 1.00 |
| INF A (H3) | 10 | 0 | 0 | 272 | 282 | 100 | 100 | 100 | 100 | 1.00 |
| INF A (H1N1) | 1 | 0 | 0 | 281 | 282 | 100 | 100 | 100 | 100 | 1.00 |
| INF B | 19 | 0 | 0 | 263 | 282 | 100 | 100 | 100 | 100 | 1.00 |
| HCoV 229E | 4 | 0 | 0 | 278 | 282 | 100 | 100 | 100 | 100 | 1.00 |
| HCoV HKU1 | 6 | 0 | 0 | 276 | 282 | 100 | 100 | 100 | 100 | 1.00 |
| Lpneu | 1 | 0 | 0 | 281 | 282 | 100 | 100 | 100 | 100 | 1.00 |
| ADV | 7 | 1 | 0 | 274 | 282 | 100 | 99.6 | 87.5 | 100 | 0.93 |
| HRhV | 60 | 7 | 2 | 213 | 282 | 96.8 | 96.8 | 89.6 | 99.1 | 0.91 |
| PIV‐3 | 18 | 1 | 1 | 262 | 282 | 94.7 | 99.6 | 94.7 | 99.6 | 0.94 |
| HBoV | 9 | 1 | 1 | 271 | 282 | 90.0 | 99.6 | 90.0 | 99.6 | 0.90 |
| HCoV OC43 | 8 | 0 | 1 | 273 | 282 | 88.9 | 100 | 100 | 99.6 | 0.94 |
| HCoV NL63 | 5 | 1 | 1 | 275 | 282 | 83.3 | 99.6 | 83.3 | 99.6 | 0.83 |
| Mpneu | 4 | 0 | 2 | 276 | 282 | 66.7 | 100 | 100 | 99.3 | 0.80 |
| B. According to cohort | ||||||||
|---|---|---|---|---|---|---|---|---|
| Total (%) | RF‐22 pos (%) | NxTAG‐RPP pos (%) | RF‐22 neg (%) | NxTAG‐RPP neg (%) | P | Sensitivity (%) | Specificity (%) | |
| Retrospective samples | 115 (100) | 80 (69.9) | 79 (68.7) | 35 (30.4) | 36 (31.3) | 1.0 | 97.7 | 87.5 |
| Prospective samples | 167 (100) | 100 (59.9) | 103 (61.7) | 67 (40.1) | 64 (38.3) | 0.25 | 95.1 | 91.8 |
| HRhV | ||||||||
| Retrospective samples | 115 (100) | 27 (23.5) | 37 (32.2) | 88 (76.5) | 78 (67.8) | 0.002 | 100 | 95.1 |
| Prospective samples | 167 (100) | 29 (17.4) | 30 (18.0) | 138 (82.6) | 137 (82.0) | 1.0 | 93.1 | 97.8 |
| PIV‐3 | ||||||||
| Retrospective samples | 115 (100) | 7 (6.1) | 8 (7.0) | 108 (93.9) | 107 (93.0) | 1.0 | 100 | 99.1 |
| Prospective samples | 167 (100) | 11 (6.6) | 10 (6.0) | 156 (93.4) | 157 (94.0) | 1.0 | 91.7 | 100 |
| INFB | ||||||||
| Retrospective samples | 115 (100) | 4 (3.5) | 3 (2.6) | 111 (96.5) | 112 (97.4) | 1.0 | 100 | 100 |
| Prospective samples | 167 (100) | 15 (9.0) | 16 (9.6) | 152 (91.0) | 151 (90.4) | 1.0 | 100 | 100 |
ADV, adenovirus; HBoV, human bocavirus; HCoV, human coronavirus; HMPV, human metapneumovirus; HRhV, human rhinovirus; INF, influenza; Lpneu, Legionella pneumophila; Mpneu, Mycoplasma pneumoniae; PIV, parainfluenza virus; RSV, respiratory syncytial virus; PPV, positive predicitve value; NPV, negative predictive value; κ (kappa), interobserver agreement.
Number and percentage of total positives and negatives detected by RF‐2 and NxTAG‐RPP in retrospective and prospective samples and the number and percentage of the most frequently found pathogens of the two cohorts, rhino‐/enterovirus (HRhV), influenza B (INFB), parainfluenza‐3 (PIV‐3).